Community Webinar: ITF Therapeutics DUVYZAT™ (givinostat)

When:
July 11, 2024 1:00PM

Join Jett Foundation’s Community Webinar Series to hear from Dr. Scott Baver from ITF Therapeutics on an introduction to DUVYZAT (givinostat) for Duchenne muscular dystrophy.

ITF Therapeutics’ DUVYZAT (givinostat)
Thursday, July 11, 2024
1pm ET | 12pm CT | 11am MT | 10am PT

 

Dr. Scott Baver

Guest Speaker

Scott Baver has his PhD in Biomedical Sciences specializing in Molecular, Cellular, and Integrative Neurosciences from Colorado State University, and his Post Doctoral Fellowship at Beth Israel Deaconess Medical Center at Harvard Medical School. He has spent the last 5 years working on neuromuscular diseases at growing biotechnology companies and most recently working with the Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis communities in Medical Affairs. Currently, Scott serves as Vice President, Head of Medical Affairs at ITF Therapeutics, LLC. In his current position, he aims to collaborate with the Duchenne community. 

Our Community Webinar Series is focused on ensuring that our Duchenne and rare disease community is better prepared for those unexpected moments, challenging medical decisions, and difficult stages when on a Duchenne journey.

No one ever expects Duchenne and there is no correct way to tackle a diagnosis, but we can always better prepare. This webinar series is an opportunity to equip yourself with more knowledge, resources, and tools for those real-life, often unanticipated, scenarios.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open